First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38033277.
- Also identified by DOI 10.1200/JCO.23.01524.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This article provides valuable insights into the use of dual immunotherapy for patients with metastatic NSCLC.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms